Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Abstract The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive ‘mid-size’ Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in...

Full description

Bibliographic Details
Main Authors: Matteo Allegretti, Alessandra Fabi, Simonetta Buglioni, Aline Martayan, Laura Conti, Edoardo Pescarmona, Gennaro Ciliberto, Patrizio Giacomini
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Next generation sequencing (NGS)
Precision medicine
Genomic aberrations
Regulatory issues
Ethics
Patient advocacy
Online Access:http://link.springer.com/article/10.1186/s13046-018-0702-x

Internet

http://link.springer.com/article/10.1186/s13046-018-0702-x

Similar Items